People: Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

6.66USD
3:41pm EDT
Price Change (% chg)

$-0.05 (-0.75%)
Prev Close
$6.71
Open
$6.64
Day's High
$6.71
Day's Low
$6.59
Volume
7,541
Avg. Vol
32,437
52-wk High
$10.98
52-wk Low
$5.81

Search Stocks

Summary

Name Age Since Current Position

Daniel Getman

58 2014 Independent Chairman of the Board

Peter Greenleaf

44 2014 Chief Executive Officer, Director

Cary Claiborne

53 2011 Chief Financial Officer

Thomas Knapp

61 2012 Executive Vice President, Chief Legal Officer and Corporate Secretary

Stanley Miele

50 2009 Senior Vice President - Sales and Marketing; President of Sucampo Pharma Americas, LLC

Andrew Smith

51 2014 Principal Accounting Officer

Anthony Celeste

75 2007 Lead Independent Director

Gayle Dolecek

71 2013 Director

Kei Tolliver

2013 Director

William Ashton

63 2009 Independent Director

Barbara Munder

68 2013 Independent Director

Maureen O'Connell

52 2013 Independent Director

Silvia Taylor

2012 Senior Vice President - Investor Relations, Public Relations and Corporate Communications

Biographies

Name Description

Daniel Getman

Dr. Daniel P. Getma, Ph.D., has been appointed as an Independent Chairman of the Board of Sucampo Pharmaceuticals, Inc., effective March 3, 2014. Dr. Getman was a Vice President of global research and development at Pfizer and Director of the company's St. Louis Laboratories, which played a key role in the company's biotherapeutics, inflammation research, and indications discovery. Dr. Getman has also held senior positions at Pharmacia, Searle, and Monsanto in research and development and medicinal chemistry, and he is the former Chairman of the Missouri Biotechnology Association (MOBIO). Dr. Getman earned a Ph.D. in Organic Chemistry from the University of Minnesota, in Minneapolis, and a Bachelor of Science degree in Chemistry from SUNY Buffalo.

Peter Greenleaf

Mr. Peter Greenleaf has been appointed as Chief Executive Officer, Director of the Sucampo Pharmaceuticals Inc. Mr. Greenleaf is the President, CEO and Board member of Histogenics, a regenerative medicine company. Prior to his leadership of Histogenics, Mr. Greenleaf served as President of MedImmune, the global biologics arm of AstraZeneca, where he was instrumental in driving the expansion of MedImmune's pipeline into over 120 clinical and pre-clinical programs and the commercialization of its marketed products. Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, where he led investment in emerging biopharmaceutical, medical device, and diagnostic companies. Prior to serving as President of MedImmune, Mr. Greenleaf was the Chief Commercial Officer of the company, responsible for its commercial, corporate development and strategy functions. Mr. Greenleaf has also held senior commercial roles at Centocor, leading the company's gastroenterology division, and has additional experience at Boehringer Mannheim and Hallmark Cards, Inc. Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. Mr. Greenleaf's previous Board appointments include the Biotechnology Industry Organization ("BIO"); the University of Maryland Baltimore Foundation, Inc.; Rib-X Pharmaceuticals; LigoCyte Pharmaceuticals; and Corridor Pharmaceuticals. He received a Master of Business Administration degree from St. Joseph's University and a Bachelor of Science degree from Western Connecticut State University.

Cary Claiborne

Mr. Cary J. Claiborne is Chief Financial Officer of Sucampo Pharmaceuticals, Inc. Mr. Claiborne joined the Company March 2011 as interim chief financial officer and was promoted to chief financial officer in October 2011. Prior to joining company, he had been president, chief executive officer and a member of the board of directors of New Generation Biofuels, Inc., of Columbia, Maryland, a NASDAQ-listed biofuel technology company, as well as its chief financial officer from 2007 until 2011. From December 2004 to November 2007, Mr. Claiborne had been chief financial officer of Osiris Therapeutics, Inc., a NASDAQ-listed stem cell therapeutics company. From December 2001 to June 2004, he was vice president-financial planning and Analysis of Constellation Energy Group, an energy supply company. From April 2000 to November 2001, he was vice president — financial planning and analysis of The Home Depot, Inc. From July 1997 to March 2000, he was vice president-financial planning and analysis at MCI Corporation. Mr. Claiborne also held a series of progressively more responsible positions in financial management and senior management, including President and chief executive officer of New Enterprise Wholesale Services at GE Capital from 1982 until 1997. Mr. Claiborne graduated from Rutgers University where he earned a B.A. in Business Administration and an MBA in Finance from Villanova University.

Thomas Knapp

Mr. Thomas J. Knapp is Executive Vice President, Chief Legal Officer and Corporate Secretary of Sucampo Pharmaceuticals, Inc. Mr. Knapp joined company in February 2010 as senior vice president, general counsel and corporate secretary and was promoted to executive vice president, chief legal officer and corporate secretary in March 2012. Previously he was of counsel at Exemplar Law Partners, LLC, and a partner and member at Knapp Law Firm beginning September 2008. From March 2003 to August 2008, he was deputy general counsel and then vice president, general counsel and corporate secretary at NorthWestern Corporation, an electric and natural gas transmission and distribution company. From January 2001 to December 2002, Mr. Knapp served as of counsel at Paul Hastings LLP (f/k/a Paul, Hastings, Janofsky & Walker LLP), and from May 1998 to December 2000 as assistant general counsel at The Boeing Company in Seattle, Washington. Mr. Knapp also served as of counsel at Paul Hastings LLP, in Washington, D.C. from May 1996 to April 1998 and he served in various in-house positions, including as labor counsel at The Burlington Northern & Santa Fe Railway Company in Chicago, Illinois and Fort Worth, Texas from September 1980 to December 1995. Mr. Knapp earned a B.A, in Political Science at the University of Illinois-Urbana and a J.D. at Loyola University of Chicago School of Law.

Stanley Miele

Mr. Stanley G. Miele is Senior Vice President - Sales and Marketing; President of Sucampo Pharma Americas, LLC., a subsidiary of Sucampo Pharmaceuticals Inc. Prior to joining Sucampo as a Sales Director, Mr. Miele managed a national level team of specialty sales representatives and engineering consultants that sold and marketed blood gas analyzers and point of care diagnostic equipment used in acute-care areas within hospitals at Abbott Point of Care beginning in October 2005. Prior to that, Mr. Miele held a series of positions at Millennium Pharmaceuticals and COR Therapeutics, prior to its acquisition by Millennium, including National Sales Director, Cardiology where he was responsible for managing the overall hospital-based cardiovascular sales function beginning January 2003. Previously, Mr. Miele was a Division Sales Representative with Abbott Laboratories’ Hospital Products Division, of Abbott Park, Illinois, and a Sales Representative for Syntex Labs, of Palo Alto, California. Mr. Miele earned a B.A. in Management/Communications from the University of Dayton.

Andrew Smith

Mr. Andrew P. Smith is Principal Accounting Officer of Sucampo Pharmaceuticals, Inc., and Director, Finance of Sucampo Pharma Europe, Ltd. In January 2012, he was promoted to Vice President, Operations & Finance of Sucampo AG. From June 2009 to February 2011, Mr. Smith provided consulting services on financial and accounting matters to Sucampo Pharma Europe, Ltd. From 2006 to 2009, Mr. Smith was Finance Director and Company Secretary of Retroscreen Virology, of London, England, Europe's leading contract virology research organization offering both clinical and analytical services. From 2004 to 2006, he was the Finance Director and Company Secretary-Europe at Clearlab, a division of 1-800 Contacts Inc. following Clearlab's 2004 acquisition of VisionTec CL Ltd., of which he was a co-founder and member of its Board of Directors. Prior to that, Mr. Smith held finance and accounting leadership positions at Biocompatibles, plc., Hydron Ltd., and Allergan Inc.'s UK-based subsidiary. Mr. Smith is a Chartered Global Management Accountant and a Fellow of the Chartered Institute of Management Accountants.

Anthony Celeste

Mr. Anthony C. Celeste is Lead Independent Director of Sucampo Pharmaceuticals Inc. Mr. Celeste served as senior vice president of regulatory affairs for Kendle International, Inc., an international clinical research organization, from 2001 until his retirement in December 2009. Prior to that, he served as the president and chief executive officer of AAC Consulting Group, Inc., an independent, regulatory consulting firm, focusing on FDA matters from 1986 until its acquisition by Kendle International in February 2001. Prior to joining AAC Consulting in 1985, Mr. Celeste served for 25 years with the FDA, most recently as director of the Office of Regional Operations. Mr. Celeste holds a B.S. in chemistry from Fordham University.

Gayle Dolecek

Dr. Gayle R. Dolecek is Director of Sucampo Pharmaceuticals, Inc. He is no longer Executive Advisor - Research and Development Affairs of the Company effective May 31, 2013. Dr. Dolecek became a director in August 2008. Dr. Dolecek became Executive Advisor, Research and Development Affairs in September 2011, reflecting his employment status change to part-time employee. Prior to September 2011, Dr. Dolecek had been Company's Senior Vice President of Research and Development since May 2006. From August 1995 to April 2006, he was a senior consultant at AAC Consulting Group, Inc., an independent FDA consulting firm. Prior to 1995, Dr. Dolecek was an officer with the U.S. Public Health Service where he served in pharmacy and health service related positions. He completed his career with the government in the U.S. FDA as director of Compendial Operations in the Center for Drug Evaluation and Research. Dr. Dolecek received his B.S./P.D. in Pharmacy from the University of Maryland and an M.P.H. in Health Services and Planning from the University of Hawaii.

Kei Tolliver

Ms. Kei S. Tolliver has been appointed as Director of Sucampo Pharmaceuticals, Inc., effective May 22, 2013. Ms. Tolliver serves as executive vice president of S&R Technology Holdings, LLC. She was previously vice president of business development at Sucampo, in which she was closely involved with Sucampo’s initial public offering and the acquisition of the company’s overseas affiliates in the U.K. and Japan. She also served as General Manager of Sucampo Pharma Europe, where she initiated and oversaw the European clinical development of lubiprostone. In May of 1998, she was Sucampo’s first full-time employee. Ms. Tolliver recently earned a J.D. degree with honors from the Columbus School of Law at the Catholic University of America in Washington, D.C. She was a member of the Catholic University Law Review and part of Columbus Community Legal Services, which offered pro bono legal services to individuals and families in the Washington, D.C. area.

William Ashton

Mr. William L. Ashton is an Independent Director of Sucampo Pharmaceuticals Inc., since October 2009. Beginning in 2013, Mr. Ashton is a principal at Harrison Consulting Group, Inc. Mr. Ashton was the founding dean of the Mayes College of Healthcare Business and Policy from 2005 to 2008 and is currently the senior vice president of external affairs at University of the Sciences in Philadelphia, Pennsylvania. From 1989 to 2005, Mr. Ashton held a number of positions at Amgen Inc., a biotechnology company, including vice president of U.S. sales and vice president of commercial and government affairs. Mr. Ashton currently serves on the boards of the National Osteoporosis Foundation and Friends of the National Library of Medicine at the National Institutes of Health. Mr. Ashton holds a B.S., Education, from the California University of Pennsylvania and a M.A., Education, from the University of Pittsburgh.

Barbara Munder

Ms. Barbara A. Munder is an Independent Director of Sucampo Pharmaceuticals, Inc., since February 27, 2013. Since 2005, Ms. Munder serves as senior advisor at Institutional Investor LLC, an international business-to-business publisher. From 2001 to 2005, she was previously executive director of the Institutional Investor Institute LLC and The Hedge Fund Institutional Forum, Institutional Investor LLC. From 2001 to 2002, she was a principal of Munder & Associates, a marketing- and web-strategy consulting firm. Also in 2001, Ms. Munder served as chief operating officer at Womenfuture LLC, a distance learning company, where she oversaw e-business strategy. From 1994 to 2000, Ms. Munder held various positions with The McGraw-Hill Companies, Inc., including senior vice president, new initiatives, with oversight for corporate-wide electronic commerce, and senior vice president, corporate affairs, with responsibility for branding, marketing, communications, and Washington affairs. Ms. Munder also serves as a director of PETsMART Inc. and Munder Realty Corporation, a private real estate firm. Additionally, she has been on the advisory board for DOAR, a private litigation information services and consulting firm; Izzo Systems, a manufacturer of ergonomically designed golf bags and straps; and Lighthouse International, a non-profit for the visually impaired. Ms. Munder holds a B.A. in political science from Elmira College and an MBA in Finance from New York University, Stern School of Business Administration.

Maureen O'Connell

Ms. Maureen E. O'Connell is an Independent Director of Sucampo Pharmaceuticals, Inc., since February 27, 2013. Since 2007, Ms. O’Connell has been the executive vice president, chief administrative officer and chief financial officer at Scholastic Inc. Ms. O’Connell has overall responsibility for finance, human resources, information technology, customer service, facilities, supply chain, and manufacturing. From 2005 to 2006, she served as executive vice president and chief financial officer at Affinion Group, Inc. From 2002 to 2004, she held a series of progressively more responsible positions, including president and chief operating officer and executive vice president, chief financial and administrative officer at Gartner, Inc. From 2000 to 2002, she worked at Barnes & Noble, as their executive vice president and chief financial officer. From 1998 to 2000, she was the chief financial officer and vice president at Publishers Clearing House. She worked as the senior vice president of finance and marketing analysis at BMG Direct from 1997 to 1998. From 1990 to 1997, she held a serious of positions at Primedia, Inc., most recently as chief financial officer and senior vice president. Ms. O’Connell is a former member of the board of directors of Beazer Homes from 2002 to 2007, where she served as audit chair for most of her tenure. Ms. O’Connell holds a B.S. in Accounting and Economics from New York University, Stern School of Business Administration and is a Certified Public Accountant in the State of New York.

Silvia Taylor

Ms. Silvia Taylor is Senior Vice President - Investor Relations, Public Relations, and Corporate Communications of Sucampo Pharmaceuticals, Inc. She brings 20 years of marketing and communications experience to Sucampo, including five years in public and media relations and 13 years in biopharmaceutical brand marketing at MedImmune and Pfizer Inc. She has experience in marketing, strategy, new product launches, social media, direct-to-consumer advertising, communications, and public health, and has held leadership roles for Viagra, Exubera, motavizumab, Synagis and FluMist as well as other pre-launch products. Ms. Taylor joins Sucampo from MedImmune where she held positions of increasing responsibility, among them Senior Director of Marketing, RSV Franchise and Senior Director of Marketing, Global Influenza Franchise. Prior to MedImmune, Ms. Taylor worked at Pfizer from 1999 to 2007, where she worked on Viagra and Exubera and in the company's consumer marketing department on patient-directed communications. Ms. Taylor's work has won numerous marketing and pharmaceutical industry awards. She graduated from the University of Virginia with a B.A. in Foreign Affairs and from Columbia Business School where she earned an MBA in Marketing and Management.

Basic Compensation

Search Stocks